Feedback
Settings

Settings

Goto Application

1. WO2022051198 - COMBINATION OF CABOTEGRAVIR AND LEVONORGESTREL

Submit observation
PermaLink
Publication Number WO/2022/051198
Publication Date 10.03.2022
International Application No. PCT/US2021/048127
International Filing Date 30.08.2021
IPC
A61K 31/4985 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
495having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
4985Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
A61K 31/567 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
56Compounds containing cyclopentahydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
565not substituted in position 17 beta by a carbon atom, e.g. oestrane, oestradiol
567substituted in position 17 alpha, e.g. mestranol, norethandrolone
A61K 45/06 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
45Medicinal preparations containing active ingredients not provided for in groups A61K31/-A61K41/132
06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61K 9/10 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9Medicinal preparations characterised by special physical form
10Dispersions; Emulsions
A61P 31/18 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
31Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
12Antivirals
14for RNA viruses
18for HIV
CPC
A61K 31/4985
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
495having six-membered rings with two ; or more; nitrogen atoms as the only ring heteroatoms, e.g. piperazine ; or tetrazines
4985Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
A61K 31/567
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids
565not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
567substituted in position 17 alpha, e.g. mestranol, norethandrolone
A61K 45/06
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
45Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61K 47/10
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
47Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
08containing oxygen, ; e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
A61K 9/0019
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9Medicinal preparations characterised by special physical form
0012Galenical forms characterised by the site of application
0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
A61K 9/10
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9Medicinal preparations characterised by special physical form
10Dispersions; Emulsions
Applicants
  • VIIV HEALTHCARE COMPANY [US]/[US]
Inventors
  • AKHAVEIN, Nima
  • ALIDORI, Simone
  • VELTHUISEN, Emile Johann
Agents
  • AJMO, Craig T.
  • BRADNEY, Alice, P.
  • ANDERSON, David
  • BRINK, Robert, H.
  • BROUGHTON, Dana
Priority Data
63/073,14001.09.2020US
Publication Language English (en)
Filing Language English (EN)
Designated States
Title
(EN) COMBINATION OF CABOTEGRAVIR AND LEVONORGESTREL
(FR) COMBINAISON DE CABOTÉGRAVIR ET DE LÉVONORGESTREL
Abstract
(EN) The present invention relates to a combination formulation of antiretroviral pharmaceutical compositions and contraceptive agents for the treatment or prevention of human immunodeficiency virus (HIV) and the prevention of pregnancy, the composition comprising an effective amount of Cabotegravir and an effective amount of a contraceptive agent. The present invention also provides a method of preventing pregnancy and treating or preventing HIV in a human by administering a therapeutically effective amount of Cabotegravir and an effective amount of a contraceptive agent to the human.
(FR) La présente invention concerne une formulation combinée contenant des compositions pharmaceutiques antirétrovirales et des agents contraceptifs pour le traitement ou la prévention du virus de l'immunodéficience humaine (VIH) et la prévention d'une grossesse, la composition comprenant une quantité efficace de cabotégravir et une quantité efficace d'un agent contraceptif. La présente invention concerne également un procédé de prévention d'une grossesse et de traitement ou de prévention du VIH chez un être humain par l'administration d'une quantité thérapeutiquement efficace de cabotégravir et d'une quantité efficace d'un agent contraceptif à l'être humain.
Latest bibliographic data on file with the International Bureau
# -